Marinus Pharmaceuticals (NASDAQ:MRNS) Announces Quarterly Earnings Results

Marinus Pharmaceuticals (NASDAQ:MRNS) announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.03), Bloomberg Earnings reports.

MRNS stock traded down $0.15 during midday trading on Friday, reaching $4.50. 284,946 shares of the stock were exchanged, compared to its average volume of 707,192. The firm has a market capitalization of $236.50 million, a P/E ratio of -5.00 and a beta of 3.25. Marinus Pharmaceuticals has a 52 week low of $2.36 and a 52 week high of $10.54.

A hedge fund recently raised its stake in Marinus Pharmaceuticals stock. Geode Capital Management LLC boosted its stake in shares of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) by 34.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 464,483 shares of the biopharmaceutical company’s stock after buying an additional 119,668 shares during the quarter. Geode Capital Management LLC owned approximately 1.15% of Marinus Pharmaceuticals worth $1,332,000 as of its most recent SEC filing. 65.39% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have issued reports on the stock. Zacks Investment Research lowered shares of Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Cantor Fitzgerald reissued a “buy” rating and set a $22.00 price target on shares of Marinus Pharmaceuticals in a report on Wednesday, May 1st. LADENBURG THALM/SH SH reissued a “buy” rating and set a $24.50 price target on shares of Marinus Pharmaceuticals in a report on Wednesday, May 1st. ValuEngine raised Marinus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, April 29th. Finally, Jefferies Financial Group started coverage on Marinus Pharmaceuticals in a research note on Tuesday, March 5th. They set a “buy” rating and a $10.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $14.94.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Rockland Register and is the sole property of of Rockland Register. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://rocklandregister.com/2019/05/18/marinus-pharmaceuticals-mrns-posts-quarterly-earnings-results-misses-expectations-by-0-03-eps.html.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Further Reading: What is diluted earnings per share (Diluted EPS)?

Earnings History for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.